Guardant Health Inc., a leading precision oncology company, has announced the approval of new compensation terms for 189 newly hired non-executive employees. On July 22, 2025, the company's Compensation Committee approved the granting of restricted stock units (RSUs) representing 239,565 shares of common stock and two non-qualified stock option awards to purchase 23,542 shares. The RSUs and stock options have a grant date of August 1, 2025, with an exercise price set at $41.42 per share. These equity awards are part of the 2023 Employment Inducement Incentive Award Plan, designed to attract new talent. The stock options vest over a three-year period, with one-third of the shares vesting after the first year and continuing monthly thereafter. Similarly, the RSUs vest annually over three years, contingent on ongoing employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.